Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Closed to Accrual

Canadian Cancer Trials Group IND.202 - Randomized Phase II Study of Interleukin-21 (rIL-21) versus Dacarbazine (DTIC) in Patients with Metastatic or Recurrent Melanoma - was closed to accrual on February 29, 2012.

We are very grateful to all participating centres, staff and patients for all their efforts and for their participation in this trial.